Literature DB >> 16463270

Comparison of the immunophenotypes of signet-ring cell carcinoma, solid adenocarcinoma with mucin production, and mucinous bronchioloalveolar carcinoma of the lung characterized by the presence of cytoplasmic mucin.

K Tsuta1, G Ishii, J Nitadori, Y Murata, T Kodama, K Nagai, A Ochiai.   

Abstract

The latest World Health Organization (WHO) classification divides adenocarcinoma mainly into adenocarcinoma mixed subtypes, acinar adenocarcinoma, papillary adenocarcinoma, bronchioloalveolar carcinoma, and solid adenocarcinoma with mucin production, and it mentions several variants, including fetal adenocarcinoma, mucinous ("colloid") adenocarcinoma, mucinous cystadenocarcinoma, signet-ring adenocarcinoma, and clear cell adenocarcinoma. In general, the mucin-producing adenocarcinoma of the lung comprises signet-ring cell carcinoma (SRCC), solid adenocarcinoma with mucin production (SA), and mucinous bronchioloalveolar carcinoma (m-BAC), mucinous ("colloid") adenocarcinomas and/or mucinous cystadenocarcinoma, and mucoepidermoid carcinoma. As SRCC, SA, and m-BAC exhibit distinct clinical features, it is important to identify differences in their immunohistochemical characteristics to better understand their histogenesis. In this study we analysed SRCC, SA, m-BAC, normal lung, and foregut-related secretory tissue for immunohistochemical differences using tissue microarrays. SRCC and SA showed high expression of MUC1 (97.4% and 100%, respectively), cytokeratin (CK) 7 (both 100%), and thyroid transcription factor-1 (TTF-1) (81.1% and 100%, respectively). They also showed low expression of MUC5AC (25.5% and 21.1%, respectively) and MUC6 (18.3% and 10.5%, respectively), whereas m-BAC showed high expression of MUC5AC (97.5%), MUC6 (75.0%), and CK7 (94.7%), but low expression of MUC1 (57.5%), and TTF-1 (27.5%). Hierarchical clustering showed that the immunophenotypes of SRCC and SA belong to the same category as alveolar lining cells, whereas m-BAC clustered onto another branch with gastric foveolar cells and bronchial goblet cells. These immunohistochemical findings support the results of our previous clinicopathological analysis of SRCC of the lung showing that SRCC occurs anatomically in the peripheral portion of the lung rather than in the bronchial gland-bearing portion. Copyright 2006 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16463270     DOI: 10.1002/path.1947

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  18 in total

1.  GNAS mutations in primary mucinous and non-mucinous lung adenocarcinomas.

Authors:  Lauren L Ritterhouse; Marina Vivero; Mari Mino-Kenudson; Lynette M Sholl; A John Iafrate; Valentina Nardi; Fei Dong
Journal:  Mod Pathol       Date:  2017-08-04       Impact factor: 7.842

2.  Cons: the confusing mucinous adenocarcinoma classification.

Authors:  Helmut H Popper
Journal:  Transl Lung Cancer Res       Date:  2017-04

3.  An immunohistochemical study of primary signet-ring cell carcinoma of the stomach and colorectum: I. Cytokeratin profile in 42 cases.

Authors:  Tadashi Terada
Journal:  Int J Clin Exp Pathol       Date:  2013-03-15

4.  Pulmonary adenocarcinoma with signet ring cell features: a comprehensive study from 3 distinct patient cohorts.

Authors:  Jennifer M Boland; Jason A Wampfler; Jin S Jang; Xiaoke Wang; Michele R Erickson-Johnson; Andre M Oliveira; Ping Yang; Jin Jen; Eunhee S Yi
Journal:  Am J Surg Pathol       Date:  2014-12       Impact factor: 6.394

Review 5.  International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma.

Authors:  William D Travis; Elisabeth Brambilla; Masayuki Noguchi; Andrew G Nicholson; Kim R Geisinger; Yasushi Yatabe; David G Beer; Charles A Powell; Gregory J Riely; Paul E Van Schil; Kavita Garg; John H M Austin; Hisao Asamura; Valerie W Rusch; Fred R Hirsch; Giorgio Scagliotti; Tetsuya Mitsudomi; Rudolf M Huber; Yuichi Ishikawa; James Jett; Montserrat Sanchez-Cespedes; Jean-Paul Sculier; Takashi Takahashi; Masahiro Tsuboi; Johan Vansteenkiste; Ignacio Wistuba; Pan-Chyr Yang; Denise Aberle; Christian Brambilla; Douglas Flieder; Wilbur Franklin; Adi Gazdar; Michael Gould; Philip Hasleton; Douglas Henderson; Bruce Johnson; David Johnson; Keith Kerr; Keiko Kuriyama; Jin Soo Lee; Vincent A Miller; Iver Petersen; Victor Roggli; Rafael Rosell; Nagahiro Saijo; Erik Thunnissen; Ming Tsao; David Yankelewitz
Journal:  J Thorac Oncol       Date:  2011-02       Impact factor: 15.609

6.  Expression of thyroid transcription factor-1 in malignant pleural effusions.

Authors:  Andras Khoor; Angela L Byrd-Gloster; Santo V Nicosia
Journal:  Pathol Oncol Res       Date:  2010-09-17       Impact factor: 3.201

7.  Co-activation of epidermal growth factor receptor and c-MET defines a distinct subset of lung adenocarcinomas.

Authors:  Daisuke Matsubara; Shumpei Ishikawa; Oguni Sachiko; Hiroyuki Aburatani; Masashi Fukayama; Toshiro Niki
Journal:  Am J Pathol       Date:  2010-10-07       Impact factor: 4.307

Review 8.  Biology of invasive mucinous adenocarcinoma of the lung.

Authors:  Yoon Jin Cha; Hyo Sup Shim
Journal:  Transl Lung Cancer Res       Date:  2017-10

9.  Prognostic analysis of primary mucin-producing adenocarcinoma of the lung: a comprehensive retrospective study.

Authors:  Yang Qu; Dan Zhao; Jing Mu; Nanying Che; Chen Zhang; Zichen Liu; Dan Su; Lijuan Zhou; Haiqing Zhang; Lixin Wei
Journal:  Tumour Biol       Date:  2015-08-09

10.  Diffuse expression of MUC6 defines a distinct clinicopathological subset of pulmonary invasive mucinous adenocarcinoma.

Authors:  Satsuki Kishikawa; Takuo Hayashi; Tsuyoshi Saito; Kazuya Takamochi; Shinji Kohsaka; Kei Sano; Noriko Sasahara; Keita Sasa; Taisei Kurihara; Kieko Hara; Yoshiyuki Suehara; Fumiyuki Takahashi; Kenji Suzuki; Takashi Yao
Journal:  Mod Pathol       Date:  2020-10-06       Impact factor: 7.842

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.